Heidelberg Pharma AG

🏃♂️ LAUFend gegen Krebs – das Team von Heidelberg Pharma AG hat ein weiteres Zeichen für eine Welt gegen Krebs gesetzt. 🏃♀️ Beim diesjährigen NCT-Lauf des National Center for Tumor Diseases (NCT) Heidelberg waren wir mit am Start und haben gemeinsam mehrere hundert Kilometer für die gute Sache zurückgelegt. Ein Einsatz ihrer Mitarbeiterinnen und Mitarbeiter, den die Heidelberg Pharma AG gerne mit einer Spende pro zurückgelegtem Kilometer belohnt. 📢 Erfahren Sie mehr über die Heidelberg Pharma AG, ihre einzigartigen #ADC-Technologien und den auf Amanitin-basierenden klinischen Hauptkandidaten HDP-101unter https://lnkd.in/eUnFbuU7 📢

Heidelberg Pharma AG is proud to be featured in Clarivate's Companies to Watch report, highlighting the most exciting companies in the ADC space right now. To learn more about our innovative approach to #ADCs using #amanitin-based compounds as the payload, read the full report at the link below. #HeidelbergPharma

📣Heidelberg Pharma AG announces report on the first half-year 2024 📣 Highlights included: 🎯 First preliminary efficacy data from the clinical trial with HDP-101 in multiple myeloma published 🎯 Presentation of preclinical and clinical data of the proprietary ADC technology platforms at the AACR Meeting 2024 🎯 HDP-101 granted Orphan Drug Designation by the FDA 🎯 Sale of a portion of future royalties for TLX250-CDx to HealthCare Royalty 🎯 Professor Andreas Pahl takes over as Chief Executive Officer 📌 Press release: https://t1p.de/4rbzc 📌 Half-year financial report 2024: https://t1p.de/9edqp

📽 Hear from our CEO, Andreas Pahl, on the groundbreaking potential of our amanitin based ADC candidates: "We can overcome resistance – we have never found any tumour cell which was resistant to the amanitin mode-of-action.” 📽   For more insights into our unique approach, including expert perspectives from Key Opinion Leaders, Jonathan Kaufman and Rakesh Dixit, Ph.D., DABT, watch our full R&D webinar here: https://lnkd.in/eVJygzyn   #ADCs #ATAC #CancerResearch

🎥 Missed Our R&D Webinar - Developing novel ADC drugs for target and highly effective cancer treatment? Catch Up Now! 🎥   Discover how Heidelberg Pharma AG is pushing the boundaries in ADC development and listen📢 to our CEO, Andreas Pahl, share his key insights on our mission and strategy.   "That’s the mission of our company – we want to create value through the development of best-in-class ADCs.”   Watch the full webinar here https://lnkd.in/eVJygzyn, featuring presentations from our management team, alongside Key Opinion Leaders in the ADC field, Jonathan Kaufman and Rakesh Dixit, Ph.D., DABT.   #ADCs #ATAC #CancerResearch

In April, the Heidelberg Pharma AG team attended AACR in San Diego, where we presented promising first efficacy data on our lead clinical #ATAC product candidate, HDP-101, targeting relapsed and refractory multiple myeloma.   Our CMO, Andras Strassz, MD, MBA, spoke to Drug Discovery World´s Megan Thomas about his key takeaways from the conference and our goal of making #Amanitin available as a cancer therapy.   Check out Drug Discovery World's latest issue, linked here: https://lnkd.in/gtSZijU9   #ADCs #ATAC #ACR24 #CancerResearch

Our lead candidate, #HDP-101, is the first #amanitin-based #ADC in clinical development and currently demonstrating promising initial first in human results in relapsed and refractory multiple myeloma in a Phase 1/2a study. Read the below insight from Optimum Strategic Communications to find out more about our unique #ATAC technology and how #HeidelbergPharma is harnessing the destructive power of alpha-Amanitin to attack cancer cells.  

📢We are happy to attend World ADC Asia 2024 in Incheon, South Korea! 📢 Learn more about Heidelberg Pharma AG Pharma´s unique ADC-technologies, which have the potential to transform the lives of cancer patients. Find a strategic partner to advance your company and discuss with George Octavian Badescu and Artjom Wischnjow business opportunities.

🎤 Heidelberg Pharma AG is excited to feature on Labiotech.eu’s Beyond Biotech podcast! 🎤   Tune in to hear our CEO, Prof. Andreas Pahl, discuss the science behind ADCs and our latest clinical trial with Jim Cornall. Discover more about our lead amanitin-based ADC, HDP-101, which targets relapsed or refractory multiple myeloma.   📌 Listen here: https://t1p.de/fk32v   #ADCs #HDP101 #BeyondBiotech #Labiotech

Heidelberg Pharma AG is pleased to announce our inclusion in Clarivate for Life Sciences & Healthcare's "Antibody Drug Conjugates (ADCs) Companies to Watch" report for 2024!   The report highlights seven companies advancing antibody drug conjugates (ADCs) to deliver highly targeted cancer treatments with minimal side effects, and we are thrilled to be among them. As a pioneer in using amanitin-based compounds for ADC payloads, we are dedicated to providing targeted cancer therapies that improve therapeutic indices and reduce side effects.   Read the full report here: https://bit.ly/4c6BjdY   #Clarivate #companiestowatch #ADC #CancerResearch